DAGRAVIT TOTAL 8 Price

Overview

Welcome to Dwaey, specifically on DAGRAVIT TOTAL 8 Drops (Oral) page.
This medicine contains an important and useful components, as it consists of Vitamin - A / B1 / B2 / B6 / C / D / d-panthenol / Nicotinamide / E.
DAGRAVIT TOTAL 8 is available in the market in concentration Combination and in the form of Drops (Oral).

DAGRA PHARMACEUTICALS is the producer of DAGRAVIT TOTAL 8 and it is imported from NETHERLANDS, The most popular alternatives of DAGRAVIT TOTAL 8 are listed downward .

Mode Of Action

Anti-inflammatory agent; mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine, but specific MOA is unknown; probably inhibits prostaglandin and leukotriene synthesis and release in colon. Action may be topical in terminal ileum and colon rather than systemic.

Indication

• Ulcerative colitis
• Ulcerative proctitis
• Crohn's Disease.

Precaution

Mild to moderate impaired renal or hepatic function (test serum creatinine before treatment, every 3 mth for 1st yr, every 6 mth for next 4 yr, then annually). Elderly; active peptic ulcer; pregnancy, lactation; patients predisposed to pericarditis or myocariditis. Counsel patients to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise during treatment; perform blood count and stop treatment if blood dyscrasias suspected. Counsel patients taking delayed release tablets to report repeatedly unbroken or partially broken tablets in their faeces. Pyloric stenosis may delay release into colon.Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment.Hypersensitivity to Sulphasalazine.In patients with a history of hypersensitivity to sulphasalazine, therapy should be initiated only under close medical supervision. Treatment must be stopped immediately if acute symptoms of intolerance occur such as abdominal cramps, acute abdominal pain, fever, severe headache and rash.Paediatric populationThere is only limited documentation for an effect in children (age 6-18 years). Lactation: Not known whether drug or metabolites are distributed into breast milk; use caution.

Side Effects

• Abdominal pain (4-8%)
• GI discomfort (4-8%)
• Headache (7%)
• Flatulence (1-6%)
• Nausea (1-6%)
• Fatigue (3%)
• Asthenia (3%)
• Malaise (3%)
• Weakness (3%)
• Fever (3%)
• Exacerbation of colitis (3%)
• Dizziness (2-3%)
• Rash (1-3%)
• Pruritus (1-3%)
• Acne (1-3%) Frequency Not Defined Pericarditis (rare)
• Pharyngitis
• Sensitivity reaction
• Cholestatic hepatitis
• Creatinine clearance decreased
• Flu like syndrome
• Discolored urine Potentially Fatal: Blood dyscrasias
• aplastic anaemia
• agranulocytosis; renal toxicity.

Contra indication

Hypersensitivity to salicylates, aminosalicylates, or any component of the product.- Severe renal impairment (GFR less than 30 mL per minute).- Severe liver impairment.- Gastric and duodenal ulcers- Children under the age of 2 years

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.